Jane J. Zara

Array ( [id] => 20248391 [patent_doc_number] => 20250297260 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-25 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSION [patent_app_type] => utility [patent_app_number] => 19/086228 [patent_app_country] => US [patent_app_date] => 2025-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 74685 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19086228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20218626 [patent_doc_number] => 20250281557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => METHODS FOR CASCADE AMPLIFICATIONS OF THERAPEUTIC PAYLOADS (CATP) & COMPOSITIONS FOR CANCER IMMUNOTHERAPIES AND GENE THERAPY [patent_app_type] => utility [patent_app_number] => 19/074698 [patent_app_country] => US [patent_app_date] => 2025-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27836 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19074698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20033629 [patent_doc_number] => 20250171851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => BIOMARKER miR-32533 FOR COGNITIVE IMPAIRMENT-RELATED DISEASE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/051528 [patent_app_country] => US [patent_app_date] => 2025-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19051528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20033629 [patent_doc_number] => 20250171851 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-29 [patent_title] => BIOMARKER miR-32533 FOR COGNITIVE IMPAIRMENT-RELATED DISEASE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/051528 [patent_app_country] => US [patent_app_date] => 2025-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2749 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19051528 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20092083 [patent_doc_number] => 20250222019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-10 [patent_title] => C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/008720 [patent_app_country] => US [patent_app_date] => 2025-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19008720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20092083 [patent_doc_number] => 20250222019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-10 [patent_title] => C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/008720 [patent_app_country] => US [patent_app_date] => 2025-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19008720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20092083 [patent_doc_number] => 20250222019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-10 [patent_title] => C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/008720 [patent_app_country] => US [patent_app_date] => 2025-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19008720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20092083 [patent_doc_number] => 20250222019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-10 [patent_title] => C6'-SUBSTITUTED LOCKED NUCLEIC ACID-MODIFIED CAP ANALOG AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/008720 [patent_app_country] => US [patent_app_date] => 2025-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15682 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19008720 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20068548 [patent_doc_number] => 20250206770 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-26 [patent_title] => CAP COMPOUNDS AND RNAS COMPRISING THE SAME [patent_app_type] => utility [patent_app_number] => 18/990530 [patent_app_country] => US [patent_app_date] => 2024-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18990530 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272230 [patent_doc_number] => 12442000 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms [patent_app_type] => utility [patent_app_number] => 18/970086 [patent_app_country] => US [patent_app_date] => 2024-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17586 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18970086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272230 [patent_doc_number] => 12442000 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms [patent_app_type] => utility [patent_app_number] => 18/970086 [patent_app_country] => US [patent_app_date] => 2024-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17586 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18970086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272230 [patent_doc_number] => 12442000 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms [patent_app_type] => utility [patent_app_number] => 18/970086 [patent_app_country] => US [patent_app_date] => 2024-12-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 17586 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18970086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19830880 [patent_doc_number] => 20250082666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-13 [patent_title] => DRUGS FOR PREVENTION OR TREATMENT OF SEPSIS [patent_app_type] => utility [patent_app_number] => 18/955967 [patent_app_country] => US [patent_app_date] => 2024-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4499 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18955967 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19910426 [patent_doc_number] => 12286627 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-29 [patent_title] => Method for preventing dsRNA bacterial solutions from being degraded by UV light and application thereof in control of silverleaf whiteflies [patent_app_type] => utility [patent_app_number] => 18/930307 [patent_app_country] => US [patent_app_date] => 2024-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 25 [patent_no_of_words] => 4038 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18930307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20227389 [patent_doc_number] => 12416032 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-16 [patent_title] => Synthetic self-amplifying MRNA molecules with secretion antigen and immunomodulator [patent_app_type] => utility [patent_app_number] => 18/801051 [patent_app_country] => US [patent_app_date] => 2024-08-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 31 [patent_no_of_words] => 34104 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18801051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20116209 [patent_doc_number] => 12365901 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-22 [patent_title] => Application of mechanical-force sensitive macrophage subset in pancreatic cancer diagnosis or prognosis evaluation [patent_app_type] => utility [patent_app_number] => 18/793716 [patent_app_country] => US [patent_app_date] => 2024-08-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 19 [patent_no_of_words] => 3366 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18793716 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264372 [patent_doc_number] => 12435350 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Complex for synthesizing nucleotide strand and method for synthesizing nucleotide strand [patent_app_type] => utility [patent_app_number] => 18/786649 [patent_app_country] => US [patent_app_date] => 2024-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11815 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18786649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20264372 [patent_doc_number] => 12435350 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-07 [patent_title] => Complex for synthesizing nucleotide strand and method for synthesizing nucleotide strand [patent_app_type] => utility [patent_app_number] => 18/786649 [patent_app_country] => US [patent_app_date] => 2024-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11815 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18786649 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19800854 [patent_doc_number] => 20250066779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGEN [patent_app_type] => utility [patent_app_number] => 18/751048 [patent_app_country] => US [patent_app_date] => 2024-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25365 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751048 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20149190 [patent_doc_number] => 20250249028 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-07 [patent_title] => APPLICATION BASED ON NUCLEOTIDES OF LACTOBACILLUS RHAMNOSUS TO PREPARE A COMPOSITION FOR ANTI-LIPOGENESIS [patent_app_type] => utility [patent_app_number] => 18/677546 [patent_app_country] => US [patent_app_date] => 2024-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 0 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18677546 [rel_patent_id] =>[rel_patent_doc_number] =>)